9.08
price up icon0.00%   0.00
after-market Dopo l'orario di chiusura: 9.20 0.12 +1.32%
loading
Precedente Chiudi:
$9.08
Aprire:
$9.06
Volume 24 ore:
1.47M
Relative Volume:
1.04
Capitalizzazione di mercato:
$437.72M
Reddito:
$91.06M
Utile/perdita netta:
$-503.14M
Rapporto P/E:
-1.0822
EPS:
-8.39
Flusso di cassa netto:
$-424.74M
1 W Prestazione:
-1.84%
1M Prestazione:
+37.16%
6M Prestazione:
+57.09%
1 anno Prestazione:
-16.08%
Intervallo 1D:
Value
$9.06
$9.17
Intervallo di 1 settimana:
Value
$9.04
$9.295
Portata 52W:
Value
$4.62
$13.47

Sage Therapeutics Inc Stock (SAGE) Company Profile

Name
Nome
Sage Therapeutics Inc
Name
Telefono
617-299-8380
Name
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
Dipendente
487
Name
Cinguettio
@SageBiotech
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
SAGE's Discussions on Twitter

Confronta SAGE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SAGE
Sage Therapeutics Inc
9.08 437.72M 91.06M -503.14M -424.74M -8.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-11 Ripresa BofA Securities Underperform
2024-11-21 Aggiornamento RBC Capital Mkts Underperform → Sector Perform
2024-10-10 Ripresa Raymond James Mkt Perform
2024-10-04 Downgrade RBC Capital Mkts Outperform → Sector Perform
2024-07-30 Downgrade TD Cowen Buy → Hold
2024-07-25 Downgrade JP Morgan Overweight → Neutral
2024-05-29 Iniziato Citigroup Sell
2024-05-29 Iniziato Robert W. Baird Neutral
2024-04-17 Downgrade BofA Securities Neutral → Underperform
2023-12-12 Iniziato Deutsche Bank Hold
2023-08-08 Downgrade Canaccord Genuity Buy → Hold
2023-08-08 Downgrade Goldman Buy → Neutral
2023-08-08 Downgrade Needham Buy → Hold
2023-08-07 Downgrade BofA Securities Buy → Neutral
2023-08-07 Downgrade Oppenheimer Outperform → Perform
2023-08-07 Downgrade RBC Capital Mkts Outperform → Sector Perform
2023-08-07 Downgrade Stifel Buy → Hold
2023-08-07 Downgrade Wedbush Outperform → Neutral
2023-07-27 Iniziato Scotiabank Sector Outperform
2023-03-13 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-01-03 Downgrade Guggenheim Buy → Neutral
2022-11-01 Iniziato Loop Capital Hold
2022-03-31 Iniziato Berenberg Hold
2021-11-02 Aggiornamento Guggenheim Neutral → Buy
2021-10-19 Ripresa Morgan Stanley Equal-Weight
2021-10-07 Downgrade Jefferies Buy → Hold
2021-09-23 Iniziato Needham Buy
2021-06-16 Downgrade Citigroup Buy → Neutral
2021-04-07 Iniziato Piper Sandler Overweight
2021-02-26 Downgrade Mizuho Buy → Neutral
2021-02-25 Reiterato H.C. Wainwright Neutral
2021-02-02 Ripresa Raymond James Mkt Perform
2021-01-22 Downgrade BMO Capital Markets Outperform → Market Perform
2021-01-04 Aggiornamento Guggenheim Neutral → Buy
2021-01-04 Downgrade RBC Capital Mkts Outperform → Sector Perform
2020-12-04 Aggiornamento Mizuho Neutral → Buy
2020-12-01 Downgrade Raymond James Outperform → Mkt Perform
2020-11-16 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-11-06 Reiterato H.C. Wainwright Neutral
2020-09-11 Aggiornamento Wedbush Neutral → Outperform
2020-08-10 Aggiornamento Raymond James Mkt Perform → Outperform
2020-05-08 Downgrade Wedbush Outperform → Neutral
2020-04-08 Downgrade Guggenheim Buy → Neutral
2020-03-18 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2020-03-06 Iniziato Citigroup Buy
2020-02-28 Reiterato H.C. Wainwright Neutral
2020-02-06 Iniziato Mizuho Neutral
2019-12-06 Reiterato RBC Capital Mkts Outperform
2019-12-05 Reiterato Guggenheim Buy
2019-12-05 Downgrade SunTrust Buy → Hold
2019-10-30 Iniziato H.C. Wainwright Neutral
2019-05-23 Iniziato Wedbush Outperform
2019-04-25 Iniziato Jefferies Buy
2018-12-14 Iniziato Wolfe Research Outperform
2018-10-11 Iniziato Oppenheimer Outperform
Mostra tutto

Sage Therapeutics Inc Borsa (SAGE) Ultime notizie

pulisher
Jun 18, 2025

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Supernus to acquire Sage Therapeutics stock for $8.50 per share - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Supernus to acquire depression drugmaker Sage - MSN

Jun 18, 2025
pulisher
Jun 17, 2025

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Update: Truist Securities Raises Price Target | SAGE - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Downgraded by Piper Sandler: Price Target Reduced | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - ACCESS Newswire

Jun 17, 2025
pulisher
Jun 17, 2025

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE: HC Wainwright Maintains Neutral Rating and $12 Price Target | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Rating Maintained as Price Target is Raised by Canacc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Price Target Raised Amid Acquisition News | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone - Benzinga

Jun 17, 2025
pulisher
Jun 16, 2025

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com

Jun 16, 2025
pulisher
Jun 16, 2025

Piper Sandler Downgrades Sage Therapeutics (SAGE) Following Acqu - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald

Jun 16, 2025
pulisher
Jun 16, 2025

These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus’ $795 million bid sufficient for Sage - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Sage, following Setbacks, to sell to Supernus for $561M - BioPharma Dive

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics By Stocktwits - Investing.com India

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Truist Securities Adjusts SAGE Therapeutics Price Target to $9 From $8, Maintains Hold Rating - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to buy Sage for up to $795 million - Axios

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Explodes Over 35% in Massive Rally on Nasdaq - Daily Chhattisgarh News

Jun 16, 2025
pulisher
Jun 16, 2025

Transcript : Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc.M&A Call - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus strikes deal to buy Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum

Jun 16, 2025
pulisher
Jun 16, 2025

SAGE Stock Rating Reiterated as Hold by Needham | SAGE Stock New - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million - inkl

Jun 16, 2025
pulisher
Jun 16, 2025

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders - Business Wire

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics shares soar after supernus acquisition deal By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston

Jun 16, 2025
pulisher
Jun 16, 2025

Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal - GuruFocus

Jun 16, 2025

Sage Therapeutics Inc Azioni (SAGE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):